Movement Disorders+ Summit 2022

Movement Disorders+ Summit 2022

Friday, September 30, 2022
Webinar -- 9:55 AM ET


*Subject to change

All times are in Eastern Time.

Day 1: Friday, September 30, 2022
All times are in ET

9:55 AM - 10:00 AM: Welcome Remarks - Marwan Sabbagh, MD, FAAN (Moderator)

10:00 AM - 11:00 AM: Targeting CGRP for the Treatment of Migraine - Nada Hindiyeh, MD (Headache Neurologist)
Migraine affects nearly 40 million people and represents the second leading cause of disability in the United States, making timely and effective treatment of major importance. In this presentation, we will review the role of calcitonin gene-related peptide (CGRP) in migraine and detail novel treatments targeting this molecule for both acute and preventive migraine treatment. 

- 5-min break -

11:05 AM - 12:05 PM: Non-CME Educational Talk
Sponsored by Neurocrine Biosciences
Understanding the Benefits of COMT Inhibition and ONGENTYS® (opicapone) Capsules for Patients With Parkinson’s Disease
Presenter: Fahd Amjad, MD, Assistant Professor of Neurology, Division of Movement Disorders/ Department of Neurology, Georgetown University Hospital

- 5-min break -

12:10 PM - 1:10 PM: Management of Neuropsychiatric Features in Alzheimer’s Disease Dementia - Marwan Sabbagh, MD, FAAN (Barrow Neurological Institute)
This presentation will discuss how to recognize the psychiatric symptoms associated with dementia, the on-label and off-label medications and strategies used in Alzheimer’s disease psychosis, and dementia-related psychosis, and new and emerging treatments for treating neuropsychiatric symptoms in Alzheimer’s disease dementia.

- 30-min break, including 5-min yoga session -

1:40 PM - 2:40 PM: A Changing Treatment Paradigm of Myasthenia Gravis: A Focus on Novel Targeted Treatments - Jonathan Katz, MD (California Pacific Medical Center) and Gil I. Wolfe, MD, FAAN (University of Buffalo)
Historically, myasthenia gravis (MG) has been treated with immunosuppressive therapy. Targeted treatments have been approved or are under investigation for MG that change the current treatment paradigm. This session will educate healthcare providers on the historical treatment of MG, how the newer agents change the treatment paradigm, and demonstrate how to treat various subtypes of MG through patient case examples.

- 5-min break -

2:45 PM - 3:45 PM: Planning Ahead: Development of a Seizure Action Plan With Rescue Medications – Jacqueline A. French, MD (NYU Grossman School of Medicine)
Adding a rescue plan and rescue therapy to an established epilepsy regimen can substantially improve outcomes. This talk will address which patients should receive rescue therapy, how to write a rescue plan, and which rescue therapies are optimal for which patients.

- 5-min break -

3:50 PM - 4:50 PM: Diagnosis and Management of Parkinson’s Disease Dementia - Marwan Sabbagh, MD, FAAN (Barrow Neurological Institute)
The presentation will discuss the cardinal features of Parkinson’s disease dementia, how it differs from dementia with Lewy bodies and Parkinson’s disease, diagnostic strategies, and pharmacologic and nonpharmacologic strategies.

4:50 PM - 4:55 PM: Closing Remarks - Marwan Sabbagh, MD, FAAN (Moderator)


Day 2: Saturday, October 1, 2022
All times are in ET

9:55 AM - 10:00 AM: Welcome Remarks - Rajesh Pahwa, MD (Chair)

10:00 AM - 11:00 AM: Distinguishing Tardive Dyskinesia From Other Drug-Induced Movement Disorders - Stuart Isaacson, MD (FIU Herbert Wertheim College of Medicine)
In this session, we will review our current understanding of tardive dyskinesia, clinical pearls to distinguish it from other drug-induced movement disorders, and how assessment of the impact of tardive dyskinesia can aid treatment decisions with first-line VMAT2 inhibitor therapy.

- 5-min break -

11:05 AM - 12:05 PM: Managing Advanced Parkinson’s Disease: Adjunctive Therapies - Rajesh Pahwa, MD (University of Kansas Medical Center)
This session will focus on patients with Parkinson’s disease, motor fluctuation, and dyskinesia and the use of adjunctive therapies to levodopa to improve their OFF time and improve their good time during the day.

- 5-min break -

12:10 PM - 1:10 PM: Hyperkinetic Movement Disorders: Importance of Differential Diagnosis When Symptoms Overlap - Victor Sung, MD (University of Alabama School of Medicine at Birmingham)
This session will discuss the various hyperkinetic movements and will provide a framework to differentiate among the various disorders that cause them. In addition, a treatment algorithm will be discussed for the specific hyperkinetic movement of chorea caused by Huntington’s disease.

- 30-min break, including 5-min yoga session -

1:40 PM - 2:40 PM: Beyond Pharmacotherapy: Advancements in Surgical Therapies for Parkinson’s Disease - Marta San Luciano, MD (University of California San Francisco)
In this session, Dr. San Luciano will discuss the indications and appropriateness for surgical therapies in Parkinson’s disease. She will review the procedure, outcomes, benefit/risks, and current state of research of deep brain stimulation, carbidopa/levodopa intestinal gel therapy, and high frequency MR-guided focused ultrasound.

- 5-min break -

2:45 PM - 3:45 PM: Updates in Diagnosis and Treatment of Essential Tremor - Daniel E. Kremens, JD, MD (Thomas Jefferson University)
In this session, Dr. Kremens will review essential tremor, including the epidemiology and recent diagnostic criteria. He also will review current and emerging treatments for essential tremor including pharmacologic, surgical, and device-aided therapies.

3:45 PM - 3:50 PM: Closing Remarks - Rajesh Pahwa, MD (Chair)


Fahd Amjad, MD

Assistant Professor of Neurology
Division of Movement Disorders/Department of Neurology
Georgetown University Hospital

Jacqueline French, MD

Department of Epilepsy/Neurology
NYU Grossman School of Medicine
New York, New York

Nada Hindiyeh, MD

Headache Neurologist 

Stuart Isaacson, MD

Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, Florida

Jonathan Katz, MD

Department of Neurology
California Pacific Medical Center
San Francisco, California

Daniel Kremens, MD, JD

Associate Professor
Movement Disorders Division
Department of Neurology
Sidney Kimmel Medical College
Jefferson University
Philadelphia, Pennsylvania

Rajesh Pahwa, MD

Chief, Parkinson and Movement Disorder Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, Kansas

Marwan Sabbagh, MD, FAAN

Professor of Neurology
Alzheimer's and Memory Disorders Division
Department of Neurology
Barrow Neurological Institute
Phoenix, Arizona


Marta San Luciano, MD, MS, FAAN

Associate Professor of Neurology
University of California, San Francisco
Attending Neurologist
Neurology/Movement Disorders and Neuromodulation Center
University of California, San Francisco Medical Center
San Francisco, California

Victor W. Sung, MD

Associate Professor
Division of Movement Disorders
Department of Neurology
University of Alabama at Birmingham
Birmingham, Alabama

Gil I. Wolfe, MD, FAAN

Irving and Rosemary Smith Professor and Chairman, SUNY Distinguished Professor
Department of Neurology
University at Buffalo/SUNY Jacobs School of Medicine and Biomedical Services
Buffalo, New York

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of neurological and movement disorders.

Target Audience 
This program is intended for a multidisciplinary audience of neurologists, psychiatrists, primary care physicians, nurses, physician associates/physician assistants, pharmacists, and other members of the healthcare team involved in the management of patients with neurologic and movement disorders.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess the latest advances in treatment options for your patients with neurologic and movement disorders
  • Develop individualized treatment strategies for optimal outcomes in your patients with neurologic and movement disorders
  • Identify best practices for improving patient care


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity will be 10.0 contact hours, including 10.0 hours of pharmacology credit

Continuing Pharmacy Education

CCO designates this continuing education activity for 10.0 contact hours (1.0 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - UANs will be specific to each topic.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate/Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 10.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.